Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 28.66%26.12B | 6.54%93.25B | 34.34%25.21B | 16.49%25.31B | -3.33%22.44B | -14.82%20.3B | 4.14%87.53B | -14.43%18.77B | 3.29%21.73B | 12.85%23.21B |
Cost of revenue | 19.34%16.55B | 3.84%62.64B | 20.85%17.03B | 13.62%16.97B | -5.64%14.78B | -11.34%13.87B | 8.06%60.32B | -5.22%14.09B | 6.97%14.93B | 17.70%15.66B |
Gross profit | 48.76%9.57B | 12.53%30.61B | 74.94%8.18B | 22.82%8.34B | 1.43%7.66B | -21.44%6.43B | -3.62%27.21B | -33.80%4.68B | -3.99%6.79B | 3.95%7.55B |
Operating expense | 2.07%5.66B | -0.45%22.23B | -2.55%5.5B | 3.84%5.76B | -2.53%5.43B | -0.50%5.55B | 6.52%22.33B | 3.50%5.64B | 3.59%5.54B | 10.79%5.57B |
Operating profit | 340.97%3.91B | 71.89%8.39B | 377.74%2.68B | 107.05%2.59B | 12.55%2.23B | -66.09%886M | -32.87%4.88B | -159.89%-966M | -27.51%1.25B | -11.39%1.98B |
Net non-operating interest income (expenses) | -64.38%-120M | -60.08%-381M | -48.44%-95M | -53.23%-95M | -110.71%-118M | -30.36%-73M | -9.68%-238M | -6.67%-64M | -24.00%-62M | -5.66%-56M |
Non-operating interest income | --4M | 210.00%31M | 100.00%16M | 200.00%3M | ---- | ---- | 400.00%10M | 700.00%8M | --1M | ---- |
Non-operating interest expense | 69.86%124M | 66.13%412M | 54.17%111M | 55.56%98M | 128.07%130M | 30.36%73M | 13.24%248M | 18.03%72M | 26.00%63M | 5.56%57M |
Net investment income | -10.38%846M | 11.40%1.43B | 414.08%223M | 122.68%83M | -73.89%177M | -9.23%944M | 9.21%1.28B | -111.29%-71M | -187.14%-366M | 433.86%678M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | 0 | 0 | 2,097.30%813M | 0 | 0 | ||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | -29.73%-48M | 69.86%-669M | 91.46%-414M | 35.75%-142M | 57.30%-76M | -101.22%-37M | -484.08%-2.22B | -937.47%-4.85B | -115.32%-221M | -11.25%-178M |
Less:Other special charges | 29.73%48M | 101.92%84M | 90.21%-171M | -35.75%142M | -57.30%76M | 101.22%37M | -386.32%-4.37B | -1,296.58%-1.75B | 115.32%221M | 11.25%178M |
Less:Write off | ---- | -91.13%585M | ---- | ---- | ---- | ---- | 2,204.90%6.59B | ---- | ---- | ---- |
Other non-operating income (expenses) | 4.69%134M | 122.38%318M | -20.75%168M | 115.71%11M | 175.00%11M | 4,366.67%128M | 189.94%143M | 327.96%212M | -288.89%-70M | 111.43%4M |
Income before tax | 155.77%4.72B | 94.87%9.08B | 144.78%2.57B | 359.21%2.44B | -31.34%2.23B | -72.12%1.85B | -46.30%4.66B | -447.24%-5.73B | -84.91%532M | 53.14%3.25B |
Income tax | 78.17%1.4B | 2.19%1.78B | 190.03%623M | 275.32%578M | -144.12%-214M | -55.98%788M | -13.06%1.74B | -1,022.67%-692M | -81.56%154M | -13.55%485M |
Net income | 213.92%3.32B | 150.02%7.31B | 138.56%1.94B | 393.65%1.87B | -11.52%2.44B | -78.12%1.06B | -56.25%2.92B | -419.92%-5.04B | -85.95%378M | 77.15%2.76B |
Net income continuous operations | 213.62%3.32B | 149.93%7.31B | 138.56%1.94B | 393.39%1.87B | -11.52%2.44B | -78.10%1.06B | -56.23%2.92B | -419.86%-5.04B | -85.95%378M | 77.15%2.76B |
Noncontrolling interests | 3,250.00%63M | -92.00%12M | 533.33%13M | -57.50%17M | -121.62%-16M | -105.13%-2M | -6.83%150M | -106.00%-3M | 0.00%40M | 138.71%74M |
Net income attributable to the company | 206.99%3.25B | 163.20%7.3B | 138.30%1.93B | 448.96%1.85B | -8.56%2.46B | -77.88%1.06B | -57.48%2.77B | -430.43%-5.04B | -87.29%337M | 75.97%2.69B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 206.99%3.25B | 163.20%7.3B | 138.30%1.93B | 448.96%1.85B | -8.56%2.46B | -77.88%1.06B | -57.48%2.77B | -430.43%-5.04B | -87.29%337M | 75.97%2.69B |
Gross dividend payment | ||||||||||
Basic earnings per share | 206.91%89.31 | 171.02%200.39 | 140.00%53.01 | 355.11%50.79 | -5.29%67.49 | -76.54%29.1 | -56.00%73.94 | -437.08%-132.54 | -83.67%11.16 | 81.14%71.26 |
Diluted earnings per share | 206.91%89.31 | 171.02%200.39 | 138.30%53.0097 | 448.74%50.79 | -5.30%67.4822 | -76.54%29.1 | -56.00%73.94 | -452.10%-138.3974 | -86.46%9.2558 | 81.14%71.26 |
Dividend per share | 0 | 22.22%55 | 44.44%32.5 | 0 | 0.00%22.5 | 0 | 0.00%45 | 0.00%22.5 | 0 | 0.00%22.5 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |